Last update July 14, 2023
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Maternal Cytomegalovirus (CMV) belongs to this group or family:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche de México of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Cytomegalovirus (CMV) is a virus that belongs to herpesvirus family. Between 30 and 100% of adults become infected throughout their lives. The infection is usually asymptomatic or very mild without treatment required. Once overcome, the virus remains latent within the body to be reactivated occasionally. Only intrauterine congenital infection has a higher rate of severe disease.
CMV is found in 50 to 97% of breastmilk samples obtained from healthy women, yet only 15 to 19% of infants become infected, and only 4% develope symptoms which may be generally fairly mild and no treatment is required (Park 2021, Prendergast 2019, Davis 2017, Jang 2016, Martins 2016, Romero 2015, García 2015, Lanzieri 2013, Kurath 2010). More serious infections have been reported (Sordelli 2015) that happened in less than 1% of at-term infants.
As lower the gestational age as greater the probability of appearance of symptomatic cases (Prendergast 2019, Martins 2016, Yoo 2015), although in some series no differences between premature infants and term infants were found (Bimboese 2022, Lanzieri 2013). On very preterm births, mostly among infants with an age lower than 30 weeks and a birthweight lower than 1,000 g, CMV infection acquired through breastmilk may cause more severe symptoms that would require treatment with Ganciclovir (Mehler 2014, Okulu2012, Lombardi 2012). However, frequency rate is usually very low without occurrence of neurological and / or other long-term sequelae (Jim 2015, Bevot 2012), albeit some authors have detected small differences on some neurologic developmental scales. (Goelz 2013)
Since some cases of especially serious infections have been reported in premature infants with GA ≤ 30 weeks or/and weight ≤ 1000 g (Anne 2016, Oulu 2012, Chiavarini 2011), some authors recommend infant feeding by using frozen and / or pasteurized breastmilk (Park 2021, Garofoli 2021,Romero 2015, Lawrence 2013 y 2004, Chiavarini 2011); Others believe that an individual decision must be made according to the clinical circumstances of every premature infant. (Lombardi 2012)
By freezing breastmilk the CMV content is reduced (Hu 2021, Balcells 2016), but not eliminated (Ogawa 2023, Omarsdottir 2015). Pasteurization does eliminate viral load in breastmilk (Prendergast 2019, Yoo 2015), however, it affects bioactive and nutrient factors of breastmilk (Lombardi 2012) and the risk for necrotizing enterocolitis may be increased (Stock 2015). Flash pasteurization at high temperature is preferable. (Red Book 2021-24)
There is a widespread consensus on that breastfeeding is not contraindicated on full-term infants whose mothers are CMV-positive on serologic tests. For most authors and scientific societies, fresh breastmilk is preferred for the routine feeding of all newborns, including preterm infants (Chen 2023, AAP 2012, Alarcon 2011, Kurath 2010, Baquero 2009), since the benefits of breastmilk outweigh the risks for clinical disease and / or neurological sequelae and because the risk associated to severe CMV disease through breast milk has been overestimated. (Red Book 201-24, Resch 2013)
See below the information of this related product: